3 results
Approved WMOCompleted
Primary Objective: The aim of the study is to show that STEMI patients who are pre-treated with crushed ticagrelor and paracetamol have a higher level of platelet inhibition after primary PCI than patients pre-treated with crushed ticagrelor who are…
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
Approved WMORecruiting
Primary objectives1A. To evaluate the effect of maximal LDL-C reduction by Evolocumab on top of high intensity lipid-lowering therapy , initiated immediately after invasive ACS treatment on functional impairment of non-infarct related artery (non-…